Please login to the form below
memantine
This page shows the latest memantine news and features for those working in and with pharma, biotech and healthcare.
Green Valley’s algae-based Alzheimer’s drug to undergo global clinical trials
2025. GV-971 became the first new drug to be approved for Alzheimer’s since memantine, which was approved in Europe in 2002 and the US in 2003.
Latest news
-
China okays Green Valley’s algae-based drug for Alzheimer’s drug
Oligomannate is the first new drug to be approved for Alzheimer’s since memantine, which was approved in Europe in 2002 and the US in 2003. ... Current drugs for Alzheimer’s like NMDA glutamate antagonist memantine and cholinesterase inhibitors
-
Roche and Evotec’s Alzheimer’s drug ineffective
disease – the cholinesterase inhibitors donepezil, galantamine and rivastigmine or glutamate NMDA receptor antagonist memantine.
-
Schultz takes Lundbeck helm after leaving Novo Nordisk
to continued generic competition to Alzheimer's therapy Ebixa (memantine) and antidepressant Cipralex (escitalopram).
-
AB Science on track for phase III data in Alzheimer's this year
The phase III trial is comparing masitinib to placebo, both given on top of background therapy with cholinesterase inhibitors or the NMDA receptor antagonist memantine, in patients with mild-to-moderate
-
Forest said to be interested in $3bn Aptalis acquisition
US for former blockbuster antidepressant Lexapro (escitalopram), as well as generic competition from 2015 for Alzheimer's disease therapy Namenda (memantine).
More from news
Approximately 0 fully matching, plus 34 partially matching documents found.
Latest Intelligence
-
Alzheimer’s: the search for a cure
If approved, it would be the first drug authorised in this indication since the 2003 approval of memantine by the FDA.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Gilead announces positive Biktarvy data for HIV and hepatitis B
- Janssen announces positive results supporting Rybrevant and lazertinib combination treatment for NSCLC
- Medscape Education Receives Joint Accreditation with Commendation to Deliver Continuing Education for Healthcare Providers
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
- NHS England to roll out continuous glucose monitors to all those with type 1 diabetes
- Sanofi and Innovent Biologics to develop oncology drugs for patients in China
- WHO launches funding appeal for greater Horn of Africa prompted by food crisis
PMHub
11 London
We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...
Latest intelligence
- Animation: Living With
- The journey from the patient's perspective...
- Achieving communication excellence by targeting the right channel at the right time
- By Danny Buckland...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
